靶向蛋白降解技术能否为抗 AD 药物研发提供潜在突破？

Can Targeted Protein Degradation Technology Provide a Potential Breakthrough in the Development of Anti-AD Drugs?

机构信息

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.

School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, People's Republic of China.

出版信息

ACS Chem Neurosci. 2024 Oct 2;15(19):3434-3436. doi: 10.1021/acschemneuro.4c00590. Epub 2024 Sep 18.

DOI:10.1021/acschemneuro.4c00590

PMID:39354828

Abstract

Recent advancements in Alzheimer's disease (AD) research have led to the approval of lecanemab and donanemab, highlighting the effectiveness of amyloid-beta (Aβ) degradation as a treatment for AD. The prospect of small molecule Aβ degraders as a potential treatment, which utilizes emerging targeted protein degradation technology, is exciting, given their ability to address some of the limitations of current therapies and their promising future in AD treatment. Despite facing challenges, these degraders are poised to become a future treatment option, harnessing scientific breakthroughs for more targeted and effective AD therapy.

摘要

近年来，阿尔茨海默病（AD）研究取得了进展，促使 Lecanemab 和 Donanemab 获得批准，这凸显了淀粉样蛋白-β（Aβ）降解作为 AD 治疗方法的有效性。小分子 Aβ 降解剂作为一种潜在的治疗方法，利用新兴的靶向蛋白降解技术，具有解决当前疗法一些局限性的潜力，在 AD 治疗方面具有广阔的前景。尽管面临挑战，但这些降解剂有望成为未来的治疗选择，利用科学突破实现更有针对性和更有效的 AD 治疗。